B -- ASSESS CASE-CONTROL DIFFERENCES IN SERUM LEVELS OF THREE ANDROGENS

Notice Date

October 18, 2001

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Room 604, Rockville, MD, 20852

ZIP Code

20852

Solicitation Number

NCI-RFQ-20001-NV

Response Due

November 1, 2001

Point of Contact

Deborah Moore, Purchasing Agent, Phone (301) 496-8609, Fax (301) 402-4513, Email dm170b@nih.gov -- Gail Zois, Contract Specialist, Phone (301) 496-8613, Fax (301) 402-4513, Email gz23u@nih.gov

Description

The National Institute of Health, National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG) proposes to enter into a sole source contract with Quest Diagnostics, Inc., P.O. Box 7780-4282, Collegeville, PA 19426. The proposed contract will provide for a continuation of laboratory services required by the DCEG for the study of case-control differences in serum levels of androgens. The total study includes 682 study subjects. The procurement will provide for completion of testosterone assays on 435 study subjects, DHEA for 482 study subjects, and androstenedione for 482 study subjects included in a study entitled "A Case-control Study of Serum Levels of Sex Steroid Hormones and Insulin-like Growth Factors and Risk of Postmenopausal Breast Cancer and Hyperplastic Benign Breast Disease". The purpose of this project is to determine whether serum levels of estrogens and androgens are related to risk of early stage breast cancer and high-risk types of benign breast disease compared to low-risk types of benign breast disease. The proposed contractor performed testosterone assays and DHEA and androstenedione assays on study subjects from this same study under previous purchase order263-MQ-636671. The objectives of this procurement are to complete the assays for testosterone, DHEA, and androstenedione for the 682 study subjects involved in the case-control study. The contractor shall perform 435 assays for testosterone, 482 assays for DHEA, and 482 assays for androstenedione using the same methodology that was used on the other samples that they have already assayed for this study. It is necessary to have Quest Diagnostics perform the laboratory services required to complete this study. It is imperative that all assays be performed by the same laboratory using the same methods in order for the results to be comparable. This notice of intent is not a request for competitive quotations. However, if an interested party believes it can perform this requirement it may submit a statement of capabilities. The capability statement and any other furnished information must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can fully meet the above requirements. An original and one copy of the capability statements must be received in the contracting office by 2 p.m. EDT (local Washington, DC time) on November 1, 2001. If further information is required please contact Debbie Moore, Purchasing Agent (301) 402-4509. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted.=20

Web Link

Visit this URL for the latest information about this (http://www.eps.gov/spg/HHS/NIH/RCB/NCI-RFQ-20001-NV/listing.html)

Record

Loren Data Corp. 20011022/BSOL001.HTM (D-291 SN5109Z7)